Prince Alfred Singh։ Understanding Antithrombin III Deficiency as a High-Risk Thrombophilia
Prince Alfred Singh, Medical Officer at Addu Equatorial Hospital (AEH), shared a post on LinkedIn:
“Understanding Antithrombin III Deficiency: A High-Risk Thrombophilia
Antithrombin III (AT III) plays a critical role as the body’s natural anticoagulant – primarily inhibiting thrombin (IIa) and factor Xa to prevent excessive clot formation.
What happens in AT III deficiency?
A reduction in this key inhibitor shifts the hemostatic balance toward thrombosis, making it one of the most clinically significant inherited thrombophilias.
Key Facts:
- Inherited in an autosomal dominant pattern
- Prevalence: approximately 1 in 3,000 individuals
- Strongly associated with recurrent venous thromboembolism (VTE)
- Arterial events are less common but can occur
Risk Perspective:
Compared to other thrombophilias such as Factor V Leiden or Protein C deficiency, AT III deficiency carries one of the highest relative risks for VTE.
Clinical Management Insights:
- Many patients require long-term anticoagulation (e.g., warfarin)
- Heparin resistance can occur due to low AT levels
- In pregnancy: heparin-based therapy is preferred
- Consider AT concentrate in selected high-risk scenarios
Clinical Takeaway:
- Early recognition is essential—especially in patients with:
- Recurrent unexplained VTE
- Strong family history of thrombosis
- Thrombosis at a young age
A tailored, lifelong management strategy can significantly reduce morbidity and prevent life-threatening complications.”
Stay updated with Hemostasis Today.
-
May 8, 2026, 09:25Athma Dias: Limitations of PT and APTT in Predicting Thrombotic Risk
-
May 8, 2026, 09:12Abhishek Kumar: New Horizons in Hemophilia B Treatment and Prevention
-
May 8, 2026, 08:19Augustina Isioma Ikusemoro: Thalassaemia is not Just a Blood Disorder – It is a Public Health Priority
-
May 8, 2026, 06:24Transforming Thrombosis Management With Antithrombotic Stewardship – Anticoagulation Forum
-
May 8, 2026, 06:03Risk-Stratified HRT Use Following VTE – NBCA
-
May 7, 2026, 17:56The Latest Clinical Data Shaping The Evolving Landscape of Hemophilia Treatment – EAHAD
-
May 7, 2026, 17:31Talha Badar: New Classical Hematology Chapter on Bleeding and Thrombosis
-
May 7, 2026, 17:26Maria Τektonidou: Gene Network Analysis Identifies STAT1 in Thrombotic APS
-
May 7, 2026, 17:23Sonu Bhaskar: Inflammatory Biomarkers in Acute Cerebral Venous Sinus Thrombosis